Acumen Q3 2021 Earnings Report
Key Takeaways
Acumen Pharmaceuticals reported its Q3 2021 financial results, highlighting the closing of its initial public offering in July 2021 with net proceeds of $168.6 million and the enrollment of first patients in INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease. The company's cash and cash equivalents totaled $135.8 million, and marketable securities totaled $94.1 million as of September 30, 2021.
Closed initial public offering in July 2021, resulting in aggregate net proceeds of $168.6 million.
Enrolled first patients in INTERCEPT-AD, a Phase 1 clinical trial of ACU193 for early Alzheimer’s disease.
Cash and cash equivalents totaled $135.8 million and marketable securities totaled $94.1 million as of September 30, 2021.
Anticipates topline data from the INTERCEPT-AD trial by the end of 2022, subject to the rate of site activation and patient recruitment.